Form 4: iTeos Director Disposes Options in Concentra Merger

iTeos Therapeutics Director David K Lee disposed of all stock options as part of the company's merger with Concentra Biosciences.

Summary

• Director David K Lee reported the disposition of 44,766 stock options in iTeos Therapeutics, Inc. (ITOS).
• The transactions occurred on August 29, 2025, coinciding with the effective time of the merger with Concentra Biosciences LLC.
• The disposition was pursuant to the Agreement and Plan of Merger dated July 18, 2025, where Concentra Merger Sub VIII, Inc. merged into iTeos Therapeutics.
• Outstanding unvested or unexercisable Company Stock Options held by service providers with accelerated vesting clauses became immediately vested and exercisable in full at the effective time of the merger.
• In-the-money options, defined as those with an exercise price less than the $10.047 per share cash amount, were canceled.
• Holders of canceled in-the-money options received a cash payment equal to the product of (1) the excess of the $10.047 cash amount over the option's exercise price ($9.84) and (2) the number of shares underlying the option, plus one non-transferable contractual contingent value right (CVR) for each underlying share.

Sentiment

Score: 7

Explanation: The filing reports a procedural event (disposition of options due to a merger) which is a neutral event in itself. However, the terms of the disposition (cash payout and CVRs for in-the-money options) are generally positive for the option holders, reflecting a successful conclusion to the acquisition.

Positives

• The merger completion indicates a successful acquisition for iTeos Therapeutics, providing liquidity and value for equity holders.
• Service providers with accelerated vesting clauses benefited from immediate vesting of their unvested stock options.
• Holders of in-the-money options received a cash payout and a contingent value right (CVR), offering immediate value and potential future upside.

Negatives

• Director Lee no longer holds any derivative securities in iTeos Therapeutics, indicating a complete exit of his option holdings in the now-acquired company.

Risks

• The future value of the contingent value rights (CVRs) is uncertain and dependent on specific future events or performance metrics as defined in the merger agreement.
• As a result of the merger, iTeos Therapeutics is no longer an independent publicly traded entity, which fundamentally changes the investment profile for former shareholders.

Future Outlook

The filing indicates the completion of a merger, meaning iTeos Therapeutics is now a subsidiary of Concentra Biosciences. The future outlook for the former public entity is now integrated into the acquiring company's strategic plans. Holders of contingent value rights (CVRs) will have a future outlook tied to the specific terms and conditions of those rights.

Management Comments

• Actions were taken by the Compensation and Leadership Development Committee of the Board of Directors of the Company in accordance with the terms of the Merger Agreement.

Industry Context

This transaction is a common occurrence in the biotechnology and pharmaceutical sectors, where larger companies acquire smaller ones to expand their pipeline, technology, or market presence. The structure, including a tender offer, merger, and specific treatment of equity awards, aligns with typical M&A practices in the industry.

Comparison to Industry Standards

• The merger structure, involving a tender offer followed by a merger, and the treatment of equity awards (cash-out of in-the-money options, accelerated vesting for certain employees, and the issuance of CVRs), is a standard approach in biotech/pharma M&A transactions.
• The inclusion of contingent value rights (CVRs) is a common mechanism used in the industry to bridge valuation gaps or allow former shareholders to participate in potential future upside of specific assets or milestones post-acquisition.

Corporate Governance

Stakeholder Impact

• Shareholders (former): Received cash consideration and contingent value rights (CVRs) for their shares/options as part of the merger.
• Employees (service providers): Those with accelerated vesting clauses saw their unvested options vest immediately, providing a liquidity event.
• Director (David K Lee): Disposed of all his reported stock options in the company as a result of the merger.

Next Steps

• The realization of value from the contingent value rights (CVRs) will depend on the achievement of specific milestones or events as defined by their terms.

Key Dates

Keywords

iTeos Therapeutics, ITOS, Concentra Biosciences, Merger, Acquisition, Stock Options, Form 4, Insider Transaction, David K Lee, Contingent Value Right, CVR